Demand and volumepositive · 3 filings
“The increase was due to higher volume ($20.6 million or 80.8%), primarily driven by increased patient demand, and favorable net pricing ($3.6 million or 14.1%).”10-Q · May 7, 2026 ↗
Xeris Biopharma Holdings, Inc.
XERS
Market read
No connected market move is active around Xeris Biopharma Holdings, Inc..
No new filing conclusion is available. 0 of 0 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
Company-4.5% todayVolume comparison unavailable
Market groupNo active group readNo durable group available
Disclosed network0 of 4 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- XERS's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if XERS's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 0 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- XERS's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods6
Price observations333
Usable filing statements50
Verified relationships4
Evidence supporting the case
- Latest annual revenue changed +43.7% year over year.
- Operating margin changed +25.1 percentage points in the latest annual period.
- Net margin changed +27.2 percentage points in the latest annual period.
- Operating cash flow covered net income at 51.67x in the latest annual period.
- Demand and volume has repeated favorable evidence across 3 filings.
Evidence challenging the case
- Diluted shares increased 17.7% in the latest annual period.
Questions before a position
- P/E is 9698% above the available filing-peer median; determine whether growth and quality justify the difference.
- EV/sales is 145% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 30, 2026
9.556m+71.1%12m+24.4%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$49.6M+146.0%$-1.55—
2022-12-31$110.2M+122.3%$-0.70—
2023-12-31$163.9M+48.7%$-0.45+1.5%
2024-12-31$203.1M+23.9%$-0.37+6.6%
2025-12-31$291.8M+43.7%$0.00+17.7%
What management says matters
Persistent and emerging business drivers
Capital investment and capacitymixed · 2 filings
“The increase in cash used by investing activities for the three months ended March 31, 2026 was due to was due to higher capital expenditures.”10-Q · May 7, 2026 ↗
Legal and regulatory exposurepositive · 1 filings
“In particular and amongst other requirements, we are required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act and are subject to the full disclosure obligations regarding executive compensation in our periodic r…”10-K · Mar 2, 2026 ↗
Macroeconomic conditionsnegative · 1 filings
“for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces; < on May 23, 2019, CMS published a final rule to allow Medicare A…”10-K · Mar 2, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 5.6× · EV/sales 6.0×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
9.55-4.5% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 30 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for XERS. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for XERS. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind XERS
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
RGSFiling-linked namesupplierMar 2, 2026 ▾
“We have entered into a supply agreement with Regis.”
JEFJefferies Financial Group Inc.partnerNov 6, 2025 ▾
“Financing Transactions In May 2022, we entered into an Open Market Sale Agreement with Jefferies LLC, as agent, dated May 11, 2022 ("Sales Agreement") for the offering, issuance and sale of up to a maximum aggregate offering price of $75.0 million of our comm…”
Depended on by
BBNXBeta Bionics, Inc.partnerFeb 24, 2026 ▾
“Research and Development Costs In May 2024, in connection with research and development activities, we entered into an exclusive worldwide License and Collaboration Agreement with Xeris which contains a number of contractual obligations.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
XERS is currently a Follower in the organic co-movement group Unknown Theme. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for XERS; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.